Regulatory information related toCOVID-19by NPRA
FAQ COVID-19 Vaccine
FAQ COVID-19 Vaccine
FAQ: Hand Sanitizers
FAQ: Hand Sanitizers
Cosmetics Section's compilation of Frequently Asked Questions regarding hand sanitizers.
Circular and Directive
Circular and Directive
on Covid-19 Pandemic
Press Releases on AEFIs of COVID-19 Vaccines
Press Releases on AEFIs of COVID-19 Vaccines
Official Notice for Site Inspections
Temporary Suspension for Site Inspections
Official notice for temporary suspension for inspection in and out of Malaysia for GMP, GDP, GCP and GLP and BE Research Centers.
Voluntary Registration of Surface Disinfectant
GUIDELINE FOR THE REGISTRATION OF SURFACE DISINFECTANT
Lot Release for
COVID-19 Vaccines
Lot Release for
COVID-19 Vaccines
Summary Reports on AEFIs of COVID-19 vaccines
Summary Reports on
AEFIs of COVID-19 vaccines
FAQ: Clinical Trials
FAQ: Clinical Trial
Guidance from Evaluation and Safety of Investigational Product Section on Managing Clinical Trials during the Covid-19 Pandemic in Malaysia.
FAQ: GMP & GDP Inspections
FAQ: GMP & GDP Inspections
FREQUENTLY ASKED QUESTIONS ON GOOD MANUFACTURING PRACTICE (GMP) AND GOOD DISTRIBUTION PRACTICE (GDP) INSPECTIONS BY NATIONAL PAHARMACEUTICAL REGULATORY AGENCY (NPRA) DURING COVID-19 PANDEMIC
Reporting ADR (including drugs used for COVID-19 treatment)
Please report ALL suspected Adverse Drug Reactions (ADRs) to the National Centre for Adverse Drug Reactions Monitoring.
Click for more info.
